0252 GMT - WuXi AppTec's sale of its Advanced Therapies unit is likely to alleviate U.S. security concerns, Citi Research analysts write in a note. The cell and gene therapy manufacturing unit is the business segment that the U.S. is worried about and affected by the Biosecure Act, which could restrict WuXi's operations in the U.S., Citi says. The sale will allow transactions to continue without interrupting patient treatments, Citi adds. Given the limited time left for the Senate to vote on the Biosecure Act under the Biden Administration, it lowers the geopolitical risks for WuXi going into 2025, Citi says. Citi retains a buy rating with a target price of HK$74.00. Shares are 3.2% lower at HK$53.85. (kimberley.kao@wsj.com)
(END) Dow Jones Newswires
December 26, 2024 21:52 ET (02:52 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。